APLT (Applied Therapeutics) יחס שווי שוק לשווי בספרים

Applied Therapeutics possesses significant pricing power over medication costs in the rare metabolic disorders segment due to the unique brain penetration of its drugs. The lack of alternatives allows the company to set premium rates with insurer support, and the metric value stands at 2.24. The stock price history on GURU.Markets complements data regarding the strict control of medication transport to the end consumer.

Investors assess capital loss risks by comparing market expectations with tangible assets. The diversified rare disease drug pipeline of Applied Therapeutics (APLT) reduces the business's regulatory dependence. The current market capitalization-to-book value ratio measures the market premium over the company's net equity. A high ratio indicates that the potential for future drug approvals is already priced in. The trend of this metric determines the degree to which the asset is overvalued relative to its book value.